Cryopreservation of hematopoietic stem cells

Berz, David; McCormack, Elise; Winer, Eric S.; Colvin, Gerald A.; Quesenberry, Peter J.

doi:10.1002/ajh.20707

Cited by 209 publications

(174 citation statements)

References 88 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…Based on this small number of dogs, it appears that, although PBHCT does not lead to a statistically significant increase in DFI in dogs with TCL, it can lead to a longer median OS when compared to historical studies using multiagent chemotherapy regimens. Because 1 dog in this study achieved postmyeloablative hematopoietic reconstitution after a second PBHCT using a cryopreserved autologous apheresis product, we suggest, that, similar to human protocols,29 cryopreserved canine apheresis products can be routinely used for both autologous and allogeneic PBHCT. Based on an apparent increase in the median OS of the dogs in this study (with 2 dogs alive >2 years after diagnosis), PBHCT may be considered as a viable alternative treatment for dogs with high‐grade TCL.…”

Section: Discussionmentioning

confidence: 92%

Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T‐Cell Lymphoma

Warry

Willcox

Suter

2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundPeripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with B‐cell lymphoma.ObjectiveTo examine apheresis and PBHCT outcomes in dogs diagnosed with T‐cell lymphoma (TCL).AnimalsFifteen client‐owned dogs diagnosed with high‐grade TCL.MethodsAfter high‐dose cyclophosphamide and rhG‐colony‐stimulating (rhG‐CSF) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment.ResultsMore than 2 × 106 CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B‐cell lymphoma 120 days post‐PBHCT. The median disease‐free interval and overall survival (OS) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS. Two of 13 (15%) dogs were alive 741 and 772 days post‐PBHCT.Conclusions and Clinical Importance PBHCT may be considered as a treatment option for dogs with TCL.

show abstract

Section: Discussionmentioning

confidence: 92%

Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T‐Cell Lymphoma

Warry

Willcox

Suter

2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Although significant improvements to cell cryopreservation procedures have been achieved (2), the improvement of current cryopreservation protocols that lead to a high mortality rate after thawing for the crystal formations that arise during freezing is a primary goal. Specifically, fast cooling forms intracellular ice crystals, which results in cell destruction and slow cooling forms ice crystals in the extracellular space, with consequent cellular dehydration.…”

Section: Introductionmentioning

confidence: 99%

Effect of trehalose on cryopreservation of pure peripheral blood stem cells

Martinetti¹,

Colarossi²,

Buccheri³

et al. 2017

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Stem cells are an important tool for the study of hematopoiesis. Despite developments in cryopreservation, post-thaw cell death remains a considerable problem. Cryopreservation protocol should limit cell damage due to freezing and ensure the recovery of the functional cell characteristics after thawing. Thus, the use of cryoprotectants is essential. In particular, the efficacy of trehalose has been reported for clinical purposes in blood stem cells. The aim of the current study was to establish an efficient method for biological research based on the use of trehalose, to cryopreserve pure peripheral blood stem cells. The efficacy of trehalose was assessed in vitro and the cell viability was evaluated. The data indicate that trehalose improves cell survival after thawing compared with the standard freezing procedure. These findings could suggest the potential for future trehalose application for research purposes in cell cryopreservation. IntroductionStem cells in biological research provide a significant source of information and, thus, contribute to the development of novel therapeutic strategies. In particular, the ability to cultivate stem cells and human hematopoietic progenitor cells in vitro is the fundamental basis for investigating hematopoiesis. An improved understanding of the mechanisms that regulate cell proliferation and differentiation during the stages of hematopoiesis would further elucidate the molecular characteristics of diseases (which are characterized by excessive expansion or a functional defect of certain immature blood components), and facilitate the identification of substances that are able to specifically protect healthy cells from the action of cytotoxic drugs.Hematopoietic stem and progenitor cells (HSPCs) may be isolated from peripheral blood (PB), bone marrow (BM) or umbilical cord blood (CB) (1).Although significant improvements to cell cryopreservation procedures have been achieved (2), the improvement of current cryopreservation protocols that lead to a high mortality rate after thawing for the crystal formations that arise during freezing is a primary goal. Specifically, fast cooling forms intracellular ice crystals, which results in cell destruction and slow cooling forms ice crystals in the extracellular space, with consequent cellular dehydration. Selection of a cryoprotectant, as well as a suitable freezing rate serves to protect cells from these adverse effects (3,4).Cryoprotectants are divided into two classes: Penetrating and nonpenetrating (5). The penetrating cryoprotectants include glycerol and 1,2-propanediol and dimethyl sulfoxide (Me 2 SO); the latter is commonly used for HSPC cryopreservation (6).The non penetrating cryoprotectants comprise polyvinyl pyrrolidone, trehalose, fructose, sucrose and glucose.Trehalose is a non-toxic disaccharide of glucose that preserves the structural integrity of the cells during freezing and thawing (7). Specifically, trehalose is found in numerous organisms, such as nematodes and yeasts, which are capable of surviving du...

show abstract

“…4 The majority of these stem cell products (SCPs) are thawed and used within months of harvesting but, increasingly, long-term storage of stem cells may also be performed as a precautionary procedure. Few data are available on the status of BM and PBSCs stored for over a decade.…”

Section: Introductionmentioning

confidence: 99%

Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years

Fernyhough

Buchan

McArthur

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

There is an increasing trend towards long-term frozen storage of haematopoietic stem cells. For such stem cells, harvested from peripheral blood (PB) or BM, it is not known if stem cell viability decreases with time. In this study, 31 separate bags of stem cell product (SCP) stored for 11-19 years (median 15 years) were assessed for total nucleated cell (TNC) count, colony forming unitgranulocyte/macrophage (CFU-GM), CD34 þ cell count and cell viability. The results were compared with the initial results obtained for the products at the time of stem cell harvest, and the percentage recovery of each parameter was plotted against time. Recovery of TNC, CD34 þ cell count and cell viability decreased with time (P ¼ o0.01) but CFU-GM did not. This study shows that SCPs harvested from PB and BM do deteriorate with long-term storage. This could have an impact on rates of engraftment.

show abstract

Cryopreservation of hematopoietic stem cells

Cited by 209 publications

References 88 publications

Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T‐Cell Lymphoma

Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T‐Cell Lymphoma

Effect of trehalose on cryopreservation of pure peripheral blood stem cells

Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years

Contact Info

Product

Resources

About